Chlorotrianisene
- Generic Name
- Chlorotrianisene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21ClO3
- CAS Number
- 569-57-3
- Unique Ingredient Identifier
- 6V5034L121
- Background
A powerful synthetic, non-steroidal estrogen. [PubChem]
- Indication
Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
- Associated Conditions
- -
- Associated Therapies
- -
Behind the LEAP-012 Trial of Lenvatinib, Pembrolizumab, and TACE in HCC
LEAP-012, a phase 3 trial, compared lenvatinib + pembrolizumab + TACE vs placebo + TACE in 480 intermediate-stage HCC patients. Primary endpoints: progression-free and overall survival; secondary: response rate and duration.
Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival
Lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival (PFS) for intermediate-stage hepatocellular carcinoma (HCC) patients compared to placebo and TACE, according to the phase 3 LEAP-012 study. Median PFS was 14.6 months vs. 10.0 months, with a hazard ratio of 0.66 (P = .0002). The treatment regimen showed manageable safety and no new concerns, suggesting it could be a new option for this patient group.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath